Paul McBarron
Net Worth
Last updated:
What is Paul McBarron net worth?
The estimated net worth of Mr. Paul McBarron is at least $7,068,582 as of 7 Sep 2025. He owns shares worth $14,202 as insider and has received compensation worth at least $7,054,380 in Cyclacel Pharmaceuticals, Inc. and Cyclacel Pharmaceuticals, Inc..
What is the salary of Paul McBarron?
Mr. Paul McBarron salary is $391,910 per year as Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director in Cyclacel Pharmaceuticals, Inc.. He also receives $391,910 as Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director in Cyclacel Pharmaceuticals, Inc..
How old is Paul McBarron?
Mr. Paul McBarron is 64 years old, born in 1961.
What stocks does Paul McBarron currently own?
As insider, Mr. Paul McBarron owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. (CYCC) | Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director | 1,886 | $7.53 | $14,202 |
What does Cyclacel Pharmaceuticals, Inc. do?
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Paul McBarron insider trading
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals key executives
Cyclacel Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Mark H. Kirschbaum M.D. (64) Senior Vice President & Chief Medical Officer
- Mr. Paul McBarron (64) Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director
- Mr. Spiro George Rombotis (66) Pres, Chief Executive Officer & Executive Director